Results 151 to 160 of about 47,495 (266)

Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases

open access: yesArthritis &Rheumatology, Accepted Article.
Objective GLP‐1 receptor agonists (GLP‐1RAs) and SGLT2 inhibitors (SGLT2is) facilitate weight loss and exhibit immunomodulatory effects, but their impact on the risk of developing autoimmune rheumatic diseases (ARDs) is unclear. We compared ARD incidence following initiation of GLP‐1RAs, or SGLT2is, vs.
Derin Karacabeyli   +4 more
wiley   +1 more source

Viral reprogramming of glial metabolism as a driver of neuroinflammation. [PDF]

open access: yesFront Immunol
Rodrigues T   +3 more
europepmc   +1 more source

Dysregulation of U12‐Type Splicing in Lupus Neutrophils

open access: yesArthritis &Rheumatology, Accepted Article.
Abstract. Objective Neutrophil dysfunction is a hallmark of systemic lupus erythematosus (SLE), but its molecular basis remains unclear. This study explores transcriptional and post‐transcriptional changes in low‐density granulocytes (LDGs), a proinflammatory neutrophil subset expanded in SLE, focusing on NADPH oxidase (Nox) function and minor intron ...
Luz P. Blanco   +11 more
wiley   +1 more source

OGFRL1 deficiency causes CRMO via pathological osteoclastogenesis, with therapeutic response to TNF inhibitor

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives To verify the pathogenesis of the OGFRL1 loss‐of‐function variant (c.30del, p. F10Ffs*110) identified in a CRMO patient and investigate the underlying mechanism. Methods Whole exome sequencing and Sanger sequencing were performed to identify and confirm the variant.
Wen Xiong   +9 more
wiley   +1 more source

New opportunities for bioscaffold‐enabled spinal cord injury repair

open access: yesBMEMat, EarlyView.
Schematic illustration of bioscaffolds for spinal cord injury repair. We summarize the effects of bioscaffold properties on SCI repair, highlight different types of bioscaffolds, various fabrication strategies, and in vivo transformations for the clinical development of SCI‐repairing bioscaffolds.
Xiaoqing Qi   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy